Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Blueprint Medicines Corp (NASDAQ: BPMC) was $83.09 for the day, down -1.55% from the previous closing price of $84.40. In other words, the price has decreased by -$1.55 from its previous closing price. On the day, 0.68 million shares were traded. BPMC stock price reached its highest trading level at $84.56 during the session, while it also had its lowest trading level at $81.24.
Ratios:
Our analysis of BPMC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.65 and its Current Ratio is at 3.71. In the meantime, Its Debt-to-Equity ratio is 2.31 whereas as Long-Term Debt/Eq ratio is at 1.95.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on October 24, 2024, initiated with a Neutral rating and assigned the stock a target price of $88.
On May 14, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $140.
Leerink Partners Upgraded its Underperform to Market Perform on May 06, 2024, whereas the target price for the stock was revised from $50 to $97.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 03 ’24 when Namouni Fouad sold 3,633 shares for $89.32 per share. The transaction valued at 324,500 led to the insider holds 69,070 shares of the business.
Albers Jeffrey W. sold 19,702 shares of BPMC for $1,685,891 on Sep 09 ’24. The Director now owns 157,557 shares after completing the transaction at $85.57 per share. On Sep 09 ’24, another insider, Albers Jeffrey W., who serves as the Director of the company, bought 19,702 shares for $85.57 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BPMC now has a Market Capitalization of 5263377408 and an Enterprise Value of 5240121856. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.51 while its Price-to-Book (P/B) ratio in mrq is 16.39. Its current Enterprise Value per Revenue stands at 14.444 whereas that against EBITDA is -15.272.
Stock Price History:
Over the past 52 weeks, BPMC has reached a high of $121.90, while it has fallen to a 52-week low of $43.89. The 50-Day Moving Average of the stock is -7.44%, while the 200-Day Moving Average is calculated to be -12.33%.
Shares Statistics:
BPMC traded an average of 651.23K shares per day over the past three months and 543070 shares per day over the past ten days. A total of 63.35M shares are outstanding, with a floating share count of 62.20M. Insiders hold about 1.82% of the company’s shares, while institutions hold 105.31% stake in the company. Shares short for BPMC as of 1727654400 were 3529107 with a Short Ratio of 5.42, compared to 1724976000 on 3962911. Therefore, it implies a Short% of Shares Outstanding of 3529107 and a Short% of Float of 6.280000500000001.
